Skip to main content

Advanced prostate cancer: the future.

Publication ,  Journal Article
Armstrong, AJ; Carducci, MA
Published in: Can J Urol
June 2005

The demonstration of a survival benefit with docetaxel for the treatment of metastatic hormone refractory prostate cancer (HRPC) is an important step forward in advancing treatment options for advanced prostate cancer. While docetaxel-based therapy has demonstrated improvement in symptomatic and quality-of-life endpoints, certainly there is a pressing need for improvement in outcomes. A number of novel agents are in basic and clinical development for advanced prostate cancer, some of which are specific to mechanisms that may be important in the development and spread of prostate cancer. Novel approaches including novel cytotoxics, immunotherapy, PSMA targeted monoclonal antibodies are among the broad categories that will be discussed in this brief review.

Duke Scholars

Published In

Can J Urol

ISSN

1195-9479

Publication Date

June 2005

Volume

12 Suppl 2

Start / End Page

42 / 47

Location

Canada

Related Subject Headings

  • Urology
  • Pyrrolidines
  • Prostatic Neoplasms
  • Male
  • Immunotherapy, Active
  • Humans
  • Forecasting
  • Atrasentan
  • Antibodies, Monoclonal
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Armstrong, A. J., & Carducci, M. A. (2005). Advanced prostate cancer: the future. Can J Urol, 12 Suppl 2, 42–47.
Armstrong, Andrew J., and Michael A. Carducci. “Advanced prostate cancer: the future.Can J Urol 12 Suppl 2 (June 2005): 42–47.
Armstrong AJ, Carducci MA. Advanced prostate cancer: the future. Can J Urol. 2005 Jun;12 Suppl 2:42–7.
Armstrong, Andrew J., and Michael A. Carducci. “Advanced prostate cancer: the future.Can J Urol, vol. 12 Suppl 2, June 2005, pp. 42–47.
Armstrong AJ, Carducci MA. Advanced prostate cancer: the future. Can J Urol. 2005 Jun;12 Suppl 2:42–47.

Published In

Can J Urol

ISSN

1195-9479

Publication Date

June 2005

Volume

12 Suppl 2

Start / End Page

42 / 47

Location

Canada

Related Subject Headings

  • Urology
  • Pyrrolidines
  • Prostatic Neoplasms
  • Male
  • Immunotherapy, Active
  • Humans
  • Forecasting
  • Atrasentan
  • Antibodies, Monoclonal
  • 3202 Clinical sciences